Who are Fluzoparib Combined With Apatinib's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluzoparib-combined-with-apatinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Fluzoparib Combined With Apatinib — Competitive Intelligence Brief

Fluzoparib Combined With Apatinib (Fluzoparib Combined With Apatinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PARP inhibitor and VEGFR-2 inhibitor. Area: Oncology.

phase 2 PARP inhibitor and VEGFR-2 inhibitor PARP, VEGFR-2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fluzoparib Combined With Apatinib (Fluzoparib Combined With Apatinib) — Jiangsu HengRui Medicine Co., Ltd.. Fluzoparib is a PARP inhibitor that blocks DNA repair, while apatinib is a VEGFR-2 inhibitor that inhibits angiogenesis, together potentially enhancing antitumor activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fluzoparib Combined With Apatinib TARGET	Fluzoparib Combined With Apatinib	Jiangsu HengRui Medicine Co., Ltd.	phase 2	PARP inhibitor and VEGFR-2 inhibitor	PARP, VEGFR-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PARP inhibitor and VEGFR-2 inhibitor class)

Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluzoparib Combined With Apatinib — Competitive Intelligence Brief. https://druglandscape.com/ci/fluzoparib-combined-with-apatinib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab